



Neurotech ships new batch of Mente Autism devices to Turkey

- *New shipment of 25 devices to recently reappointed distribution partner ESE Pazarlama*
- *New distribution opportunities to be explored in the United Kingdom*

Perth, Australia & Malta – 10 July 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has shipped a new batch of Mente Autism devices to Turkey.

The shipment of 25 devices was completed to upgrade existing users of Mente 2 to Mente Autism following receipt of the initial agreed part payment last week, with the balance to be paid once the devices are received in Turkey.

Delivery of the new shipment to Turkish distributor ESE Pazarlama (previously MBM Medikal) follows the recent renewal of the distribution partner’s contract for a further three years.

“This is another milestone for Neurotech and gives us the confidence to step up our activity in Turkey with ESE Pazarlama. With 20,000 children registered with Autism Spectrum Disorder in Turkey, and many more expected to be unregistered, this market has huge potential and we look forward to creating new commercial opportunities in the region,” Neurotech’s CEO Wolfgang Storf said.

NEUROTECH ATTENDS THE AUTISM SHOW IN THE UK

Neurotech has attended this year’s instalment of The Autism Show, held in Manchester, UK, from 30 June to 1 July 2017. The Autism Show is the United Kingdom’s national event for autism and the largest event in the country dedicated to the autism community with over 3,000 attendees. It offers information, advice, products and services focused on autism. Parents, medical professionals and distributors who visited Neurotech’s booth were given information about the product and product demos.

Neurotech’s CEO, Wolfgang Storf said: “The Autism Show is the first autism event we attended in the UK and gave us the opportunity to present Mente Autism to both parents of children with ASD, as well as potential distribution partners. We will be reaching out to several contacts made during the show to explore future opportunities in the region.”

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420